Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
|Articles|March 5, 2008
Hypertrophic Cardiomyopathy Rare in Elite Athletes
New research suggests that routine echocardiographic screening of elite athletes to detect hypertrophic cardiomyopathy (HCM) may not be warranted, as HCM is extremely rare in this population, according to an article published in the March 11 issue of the Journal of the American College of Cardiology.
Advertisement
Advertisement
Related to this article
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.
A Bifidobacterium-based synbiotic was well tolerated and increased colonization of administered strains in infants and toddlers.
Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.
Baseline severity and clinical phenotype may help predict response to systemic therapy in children with alopecia areata.
Pediatricians can help teen athletes navigate sports supplements by prioritizing nutrition and identifying products to support, limit, or avoid.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA approves rebisufligene etisparvovec, first gene therapy for Sanfilippo syndrome type A
3
Pegcetacoplan reduces proteinuria, stabilizes kidney function in adolescents with C3G and IC-MPGN
4